• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Angiogenesis Inhibitors and Stimulators - Global Business Strategic Report Product Image

Angiogenesis Inhibitors and Stimulators - Global Business Strategic Report

  • ID: 1575298
  • May 2012
  • Region: Global
  • 675 Pages
  • Global Industry Analysts, Inc

This report analyzes the worldwide markets for Angiogenesis Inhibitors and Stimulators in US$ Million by the following Product Segments: Angiogenesis Inhibitors, and Angiogenesis Stimulators. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Middle East, and Latin America. The report profiles 69 companies including many key and niche players such as Abbott Laboratories, Adnexus Therapeutics, Inc., Æterna Zentaris Inc., Amgen, Inc., Angstrom Pharmaceuticals Inc., AstraZeneca Plc, Bayer HealthCare AG, Callisto Pharmaceuticals, Inc., Celgene Corporation, Celltech Group Plc., Cephalon Inc., Eisai Inc., Eli Lilly And Company, ImClone Systems Inc., EntreMed Inc., GenVec Inc., Genzyme Corp., GlaxoSmithKline plc, Merck KGaA, Novartis, OSI Pharmaceuticals, Inc., Eyetech, Inc., Pfizer Inc., Progen Industries, Regeneron Pharmaceuticals, Roche, Genentech Inc., Chugai Pharmaceutical Co. Ltd., Silence Therapeutics, and ThromboGenics Limited. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For information on site licence pricing please click on Enquire before buying

ANGIOGENESIS INHIBITORS AND STIMULATORS

A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
1. Angiogenesis Inhibitors I-3
2. Angiogenesis Stimulators I-4

II. Executive Summary

1. MARKET OUTLOOK II-1
Angiogenesis: In the Spotlight II-1
Angiogenesis: A Preview II-1

2. MARKET OVERVIEW II-2
Angiogenesis Makes Inroads: A Retrospect II-2
Angiogenesis: Ushering-In a New Era II-2
Angiogenesis: Fact File II-3
Milestones in Research Achieved Over the Years II-4
Anti-Angiogenic Drugs Market - An Overview II-5
Angiogenic Inhibitors Market to Surge II-5
The Long Journey for Anti-Angiogenesis Therapies II-5
Approved Anti-Angiogenesis Drugs in the Market II-6
Select FDA-Approved Anti-Angiogenic Drugs/ Therapeutics In
Oncology By Type Monoclonal Antibody Therapies II-6
Small Molecule Tyrosine Kinase Inhibitors II-7
Inhibitors of mTOR II-8
Other Anti-Angiogenic Agents II-8
Leading Drugs in the Market II-9
Avastin Leads the Fray II-9
Table 1: Select Leading Drugs in the Global
Anti-Angiogenesis Market: Annual Sales in US$ Million for
Years 2008 & 2009 (includes corresponding Graph/Chart) II-9
Overview of Select Leading Drugs II-10
Avastin II-10
Survival Benefit Conferred by Avastin II-11
Mechanism of Action II-12
General Mode of Delivery II-12
Side Effects Elicited on Administering Avastin II-12
ERBITUX™ (Cetuximab) II-12
Regulatory Approvals II-13
Erbitux in Head and Neck Cancer II-13
Glivec/Gleevec (imatinib mesylate) II-14
Herceptin (Tractuzumab) II-14
Sutent (Sunitinib) II-14
Other Regulatory Approvals II-15
Sunitinib in Various Indications II-15
Sunitinib in Renal Cell Carcinoma (RCC) II-15
Sutent in Gastrointestinal Stromal Tumors (GIST) II-16
Cost Related Issues II-16
Tarceva (Erlotinib) II-16
Other Regulatory Approvals II-16
Thalomid® (Thalidomide) II-17
Table 2: Thalomid - Percentage Breakdown Based on Relative
Oncology Application (includes corresponding Graph/Chart) II-17
Cilengitide II-18
Imiquimod II-18
Angiogenesis Inhibitors - Pipeline Status II-19
Select Anti-Angiogenesis Drugs in Phase III Development II-19
Select Anti-Angiogenesis Drugs in Phase II Development II-20
Select Anti-Angiogenesis Drugs in Phase I Development II-21
Select Approved Indications of Anti-VEGF/VEGFR Drugs II-21
Novel Targets for Anti-Angiogenic Activity II-22
Select Approved HER Receptor-Targeting Drugs II-22
Select Approved m-TOR Inhibitors II-22
Integrins II-23
Select Integrin Targeting Drugs under Development II-23
Angiogenic Inhibitors - By Disease Application II-23
Cancer II-23
Various Types of Cancers Targeted by Angiogenesis
Inhibitors in Phase III Clinical Development II-24
Diabetic Retinopathy II-24
Female Reproductive Cycle II-24
Psoriasis II-24
Inflammatory Diseases II-25
Table 3: Classification of Anti-Angiogenic Compounds Based
on Most Commonly Targeted Indication (includes
corresponding Graph/Chart) II-25
Angiogenesis Inhibitors in Eye Related Diseases II-25
Age-Related Macular Degeneration II-26
Wet AMD II-26
Dry AMD II-26
Select Anti-Angiogenic Drugs Approved by FDA for Treatment
of Eye Diseases II-27
Angiogenesis Inhibitors in Dermatology II-27
Select Drugs/Therapeutics with Angiogenic Mode of Action
Approved by FDA for Dermatology II-27

3. MARKET TRENDS II-28
Cancer - The Key Target Indication for Research in Anti-
Angiogeneis Drugs II-28
Avastin Continues to Record Robust Growth II-28
New Markets Offer Higher Potential for Herceptin II-28
Increased Use Drives Tarceva's Growth in Developed Markets II-28
Angiogenesis Inhibitors Continue to Dominate RCC Drug Market II-29
Votrient to Lead Renal Cell Carcinoma (RCC) Drug Market II-29
Table 4: Leading Drugs in the Global Second Line Advanced
Renal Cell Carcinoma Market (2010): Percentage Breakdown by
Value Sales for Nexavar, Torisel, Afinitor, Avastin, and
Others (includes corresponding Graph/Chart) II-30
Clinical Benefits of Votrient Over Sutent II-30
US FDA Revokes Avastin Approval for Breast Cancer II-31

4. ANGIOGENESIS REPERTOIRE II-32
An In-depth Insight into Angiogenesis II-32
Angiogenesis: At a Glance II-32
Requisites for Angiogenesis II-32
Endogenous Regulators of Angiogenesis II-33
Angiogenic Process: Sequence of Events II-33
Angiogenesis Process in Children II-34
Angiogenesis Process in Adults II-34
The Process of Angiogenesis in Thyroid Gland II-34

5. ANGIOGENESIS INHIBITORS II-35
Angiogenic Inhibitors: Basic Framework II-35
Natural Inhibitors II-35
Thrombospondin II-35
Interferon II-35
Cryptic Inhibitors II-35
Other Natural Inhibitors II-35
Natural Sources for Anti-Angiogenic Action II-36
Potential Anti-Angiogenic Drugs of Natural Origin II-36
Angiogenic Inhibitors: On the Verge of Attaining Superior
Clinical Efficacy II-36
Endogenous vs Synthetic Agents II-36
Angiogenesis Inhibitors: Classification Based on Source of
Origin II-37
Anti-Angiogenic Molecules: Classification Based on Mode of Action II-37
Broad Overview of Anti-Angiogenic Therapies II-37
Pre-Requisites for Any Drug to be an Angiogenic Inhibitor II-38
Specific Therapeutic Strategies of Anti- Angiogenesis Agents II-38
Inhibiting Angiogenesis In Vivo II-39
Antiangiogenic Tumor Therapy II-39
Antivascular Therapy: Adding a New Dimension II-39
MMPs - Exhibiting Dual Role II-39
Angiogenesis Inhibitors Vs Standard Chemotherapy II-40
Comparison Between Cytostatic Antiangiogenesis and Cytotoxic
Chemotherapy II-40
Proteoglycan Mixture: Therapeutic Powerhouse II-41
Features of VascuStatin II-41
Angiogenesis Inhibition Versus Cytotoxic Therapy II-41
Relationship Between Copper and Angiogenesis II-41
Anti-Angiogenesis Action of Pencillamine II-42
Outline of Steps Involved in Drug Discovery for Angiogenesis II-42
Drug Delivery: Their Influence on Therapeutics II-42

6. PROMOTERS OF ANGIOGENESIS/ ANGIOGENESIS STIMULATORS II-44
Angiogenesis Stimulators II-44
Growth Factors II-44
Angiogenic Stimulators in the Market II-44
Stimulators Exhibiting Profound Influence on Angiogenesis II-44
Vascular Endothelial Growth Factor (VEGF) II-44
VEGF and Their Influence on Diabetes and Diabetic Retinopathy II-45
Fibroblast Growth Factors (FGFs) II-45
Basic Fibroblast Growth Factor (bFGF) II-45
Placental Growth Factor (PlGF) II-45
Recombinant a4 Fragment II-46
Hepatocyte Growth Factor/ Scatter Factor (HGF/SF) II-46
Angiogenin II-46
Platelet Derived Endothelial Cell Growth Factor II-46
Applications of Angiogenic Stimulators vis-à-vis Disease
Perspective II-46
Cardiac Diseases II-46
Wound Healing and Burns II-46
Critical Limb Ischaemia II-47
Status of Angiogenic Inducers II-47
Angiogenic Therapies for Tissue Repair & Regeneration II-47
Select Devices Supporting Therapeutic Angiogenesis II-47
Angiogenesis in Ischemic Heart II-48
Factors Influencing Ischemic Angiogenesis II-48
Angiogenesis and CAD II-48
Angiogenesis in Wound Healing II-49
Factors Stimulating Wound Angiogenesis II-49
Factors Impairing Wound Angiogenesis II-49
Angiogenic Therapy Vs. Conventional Therapy II-49
Types of Angiogensesis II-50
Excessive Angiogenesis II-50
Insufficient Angiogenesis II-50
Tumor Angiogenesis II-50
Sequence of Actions II-50
Angiogenesis and Tumor Progression II-50
Oncogenes vis-à-vis Potential Pro-angiogenic Activities on
Tumor Angiogenesis II-51
Role of Angiogenesis in Skin Diseases II-51
Select Drugs & Their Targeted Application II-52
Analysis of Developmental Activities Between Decades II-52
Role of Enzymes and Inflammatory Cells in Angiogenesis II-53
Angiogenic Imbalance Augments Retinal Neovascularization II-53
Oncogenes & VE -cadherin - A Facilitating Role II-53

7. PRODUCT APPROVALS AND LAUNCHES II-54
FDA Withdraws Approval of AstraZeneca's NDA for IRESSA (
gefitinib) Tablets II-54
Pfizer Obtains European Approval for SUTENT® to Treat
Pancreatic NET II-54
Novartis Obtains FDA Approval of New Indication for Afinitor II-54
FDA Approves Herceptin for Treating Metastatic Adenocarcinoma II-55
Roche Introduces Avastin in China II-55
Pfizer Japan Receives Clearance for Torisel in Japan II-55
GSK Obtains European Commission's Conditional Marketing
Approval for Votrient II-56
FDA Approves Tarceva® for Maintenance Treatment of NSCLC II-56
FDA Approves GlaxoSmithKline's Votrient II-56
European Commission Grants Clearance to Torisel for Mantle
Cell Lymphoma II-56
Genetech Receives FDA Approval for Avastin in Renal Cell
Carcinoma II-57
FDA Approves Bevacizumab as Second Line Treatment for
Glioblastoma II-57
Novartis Obtains FDA Approval of Afinitor for Treating Renal
Cell Cancer II-58

8. PRODUCT APPROVALS AND LAUNCHES - A HISTORIC PERSPECTIVE BUILDER II-59
FDA Grants Clearance for Gleevec in Treatment of
Gastrointestinal Stromal Tumor II-59
Celgene's Thalidomide Pharmion™ Receives EC Clearance for
Treating Multiple Myeloma II-59
Genentech Obtains FDA Approval for Avastin in Breast Cancer II-59
FDA Approves Nexavar for Treatment of Hepatocellular Carcinoma II-60
Wyeth Receives EC Clearance for TORISEL in Advanced Renal Cell
Carcinoma II-60
OSI and Roche Announce Approval of Tarceva® in Japan II-60
ImClone Obtains FDA Label Expansion for Erbitux®, as Third
Line Therapy in mCRC II-60
REVLIMID® Obtains Swissmedic Authorization in Switzerland II-61
REVLIMID® Receives Marketing Approval in European Union II-61
Wyeth Obtains FDA Clearance for Marketing Torisel II-61
Chugai Obtains Approval for Avastin in Japan II-62
Pfizer Obtains FDA Approval for Sunitinib in Metastatic Renal
Cell Carcinoma II-62
FDA Approves Herceptin in HER2-Overexpressing Breast Cancer
Treatment II-62
Genentech Receives FDA Approval for Bevacizumab in Non-Small
Cell Lung Cancer II-63
Amgen Obtains FDA Approval for Vectibix Treating mCRC II-63
FDA Grants Marketing Approval for Lucentis in Wet AMD II-63
Celgene Obtains FDA Clearance for Revlimid in Multiple Myeloma II-64
FDA Approves Bevacizumab for Second Line Treatment of
Metastatic Colorectal Cancer II-64
Celgene Obtains FDA's Accelerated Approval for THALOMID II-65
Celgene Obtains sNDA Approval for THALOMID from FDA II-65
ImClone Obtains FDA Clearance for Erbitux® in the treatment of
SCCHN II-65
Pfizer's Sutent Receives FDA Nod for Treatment of
Gastrointestinal Stromal Tumor II-66
Celgene Receives FDA's Subpart H Approval for Revlimid in
Myelodysplastic Syndromes II-66
US FDA Approves OSI's Tarceva® for Treating Pancreatic Carcinoma II-66

9. RECENT INDUSTRY ACTIVITY II-68
Valeant to Take Over Eyetech II-68
Teva Acquires Cephalo II-68
Genentech to Carry Out Additional Trial of Avastin in Her2-
negative mBC II-68
Pfizer to Seek regulatory Clearance for Axitinib in Europe and US II-68
FDA to Withdraw Avastin's Approval for Breast Cancer II-69
Eyetech Receives QTDP Grant To Develop Extended- Release
Formulation of Macugen® II-69
sanofi-aventis and Regeneron to Continue VELOUR Trial as Planned II-69
EntreMed Enters into Financing Deal for ENMD-2076 Development II-69
Chugai Pharmaceuticals Fulfills Condition for Avastin's Approval II-70
Gilead Sciences to Take Over CGI Pharma II-70
Mersana Commences XMT-1107 Phase I Clinical Trial II-70
Astellas Pharma Acquires OSI Pharmaceuticals II-71
Roche to Conduct a Trial on Anti-Cancer Antibody TB-403 II-71
Mersana Therapeutics Inks License Agreement With Teva II-71
Acceleron Publishes Pre-clinical Data Study on ACE-041 II-72
Antisense Raises Capital to Continue Phase III Trabedersen Trial II-72
GSK Receives Positive Opinions from EMEA for Two Cancer Medicines II-72
EMEA Issues Positive Opinion on GSK's Votrient II-73
EMEA Issues Positive Opinion on GSK's Anti Cancer Drug
Candidate, Tyverb II-73
Abbott Enters into Licensing Agreement with Pierre Fabre II-73
Arno Therapeutics Inks Global Licensing Agreement with OSU II-73
BI Initiates Late Stage Clinical Trials for Two Oncology Drug
Candidates II-74
AnGes Obtains US FDA Approval for Phase III Trial of Collategene™ II-74
Silence Therapeutics and Intradigm Merge II-74
Mersana Launches First Phase of XMT-1107 Clinical Trial II-75
ImClone Receives Complete Response Letter for Erbitux® sBLA
From FDA II-75
Oxigene Releases Encouraging Data from OXi4503 Pre-clinical
Studies II-76
Potentia Enters into Licensing and Purchase Option Deal with
Alcon II-76
Quark Receives Additional Patents for RTP 801 Gene Targeting
Compounds II-77
Simcere Enters into Collaboration Deal with OSI Pharmaceuticals II-77
Pfizer Acquires Wyeth in Cash & Stock Merger II-78
Gene Signal Releases Interim Results from Phase II Study on
GS-101 II-78
Onco to Conduct Second Phase Trial of Fusos OTS102 II-78
Green Cross Obtains US FDA Approval for Greenstatin Clinical
Trial II-79
OXiGENE Acquire Symphony ViDA II-79
Roche Releases Positive Results from Phase III Trial of Lucentis II-79
Pfizer Halts Phase III Sutent Study for Colorectal Cancer II-80
Morphotek Obtains FDA Clearance for MORAb-004 IND Application II-80
GlaxoSmithKline Files MAA for Pazopanib in EU II-80
Roche Acquires Genentech II-80
Fuso Commences Phase II/III Clinical Trail for OTS102 II-81

10. STRATEGIC CORPORATE DEVELOPMENTS - A HISTORIC PERSPECTIVE BUILDER II-82
EntreMed to Funnel Resources on ENMD-2076 Development II-82
OmegaGenesis Enters Into Collaboration with Mayo Clinic for
Angiogenesis Research II-82
Eli Lilly Acquires ImClone Systems II-82
EntreMed Demonstrates Antitumor Effects of ENMD-2076 II-83
EntreMed Collaborates with JSB for ENMD-2076 Business Development II-83
Circadian Technologies Limited Acquires Vegenics II-83
Fuso and OTS to Initiate Phase II Trial for OTS102 II-83
EntreMed Releases Pre-Clinical Findings of ENMD-2076 in
Multiple Myeloma II-83
Merck Serono Inks Development and Licensing Agreement with
Bionomics II-84
Roche Inks Licensing Agreement with ThromboGenics and
BioInvent for TB-403 II-84
Aida Initiates Pre-Clinical Development of New Anti-Cancer Drug II-85
Cyclacel Pharmaceuticals Releases Pre-Clinical Data of CYC116 II-85
Astellas and CoMentis Ink Agreement to Develop and
Commercialize Beta- Secretase Inhibitors II-86
Kringle Pharma's NK4 Receives Patent Approval in Japan II-86
UCB Releases Phase II Results of CDP791 in NSCLC Treatment II-87
Celgene Takes Over Pharmion II-87
REVLIMID® Obtains Orphan Drug Designation in Japan II-87
TRACON Commences Phase I Clinical Trial on TRC105 II-87
Ark Therapeutics to Acquire Lymphatix II-88
Access Takes Over Somanta II-88
Pfizer Takes Over CovX II-88
Callisto Restructures Licensing Agreement with Genzyme for
Atiprimod II-89
EntreMed Receives FDA Approval for ENMD-2076 IND Application II-89
EC Grants Orphan Medicinal Status to REVLIMID for Treatment of
CLC II-90
Bristol-Myers Squibb Snaps Up Adnexus Therapeutics II-90
Morvus Takes Over Two Companies II-90
Merck Inks Agreement with BMS and ImClone for Erbitux®
Development And Commercialization II-91
FDA Issues a Safety Labeling Update for Bevacizumab Drug II-91
Fuso Initiates Phase I Clinical Study for OST102 Angiogenesis
Inhibitor II-91
CRC to Support Bionomics in BN069 Development II-92
Peregrine Secures Licensing Rights for B2GP1 Angiogenesis
Inhibitor II-92
AnGes's Angiogenesis-Stimulating Drug Meets Primary End-Point
in Phase III Study II-92
ImClone Annuls Development Agreement with UCB II-92
ArQule Partners with Kyowa Hakko in Cancer Compound II-93
Samaritan Snaps Up Metastatin Pharmaceuticals II-93
EU Approves €2 Million Grants for VASOPLUS Consortium II-93
MGH Cancer Center Reports Results of AZD2171 Phase II Trial II-93
AVEO Inks Exclusive Licensing Agreement with Kirin for Novel
Anti-Cancer Compound II-94
Sangamo and Edwards Ink Angiogenesis Asset Purchase Agreement II-94
Covalon Secures Perfusion's Gene Therapy Solutions II-94
Vical Strengthens Angiogenesis and Poloxamers IPR Portfolio II-95
Biomira Takes Over ProIX Pharmaceuticals II-95
FDA Gives Out Warning on Bevacizumab Drug II-95
Athenagen Merges with Zapaq II-95
Tigris Secures Global Licensing Rights to Develop and
Commercialize New Cancer Therapies II-96
Bayer Yakuhin Files Marketing Application for Nexavar in Japan II-96
Athenagen Purchases Assets of Osprey Pharmaceutical II-96
Amgen Acquires Abgenix II-96
Genmab Enters Exclusive Licensing Agreement with Bionomics II-97
OSI Pharmaceuticals Acquires Eyetech Pharmaceuticals II-97
FDA Changes Labeling of Iressa, Limiting Use to NSCLC II-97
Schering AG and Novartis Signs a Agreement to Commercialize
Angiogenesis Inhibitor, PTK787 II-98
Bausch & Lomb Signs an Option Agreement with PTC Therapeutics II-98
Bausch & Lomb Receives License from Cephalon, Inc II-98
Pharmacopeia Signs a Licensing Agreement with Allergan II-99
Xantos Biomedicine and Cryptome Enters into Licensing Agreement II-99
EntreMed Receives US Patent II-99

11. FOCUS ON SELECT GLOBAL PLAYERS II-100
Abbott Laboratories (USA) II-100
Adnexus Therapeutics, Inc. (USA) II-100
Æterna Zentaris Inc. (Canada) II-100
Amgen, Inc. (USA) II-101
Angstrom Pharmaceuticals Inc. (USA) II-101
AstraZeneca Plc. (UK) II-102
Bayer HealthCare AG (Germany) II-102
Callisto Pharmaceuticals, Inc. (USA) II-103
Celgene Corporation (USA) II-104
Celltech Group Plc. (UK) II-104
Cephalon Inc. (USA) II-104
Eisai Inc. (USA) II-105
Eli Lilly And Company (USA) II-105
ImClone Systems Inc. (USA) II-105
EntreMed Inc. (USA) II-106
GenVec Inc. (USA) II-107
Genzyme Corp. (USA) II-107
GlaxoSmithKline Plc (UK) II-107
Merck KGaA (Germany) II-108
Novartis (Switzerland) II-108
OSI Pharmaceuticals, Inc. (USA) II-109
Eyetech, Inc. (USA) II-110
Pfizer Inc. (USA) II-110
Progen Industries (Australia) II-111
Regeneron Pharmaceuticals II-111
Roche (Switzerland) II-112
Genentech Inc. (USA) II-113
Chugai Pharmaceutical Co. Ltd. (Japan) II-114
Silence Therapeutics II-115
ThromboGenics Limited (Ireland) II-115

12. GLOBAL MARKET PERSPECTIVE II-116
Table 5: World Recent Past, Current & Future Analysis for
Angiogenesis Inhibitors & Stimulators by Geographic
Region/Country - US, Europe and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2003 through 2010 (includes corresponding Graph/Chart) II-116

Table 6: World Historic Review for Angiogenesis Inhibitors &
Stimulators by Geographic Region/Country - US, Europe and Rest
of World Markets Independently Analyzed with Annual Sales in
US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-117

Table 7: World 15-Year Perspective for Angiogenesis Inhibitors
& Stimulators by Geographic Region/Country - Percentage
Breakdown of Dollar Sales for US, Europe and Rest of World
Markets for Years 2003, 2011 and 2017 (includes corresponding
Graph/Chart) II-118

Table 8: World Recent Past, Current & Future Analysis for
Angiogenesis Inhibitors by Geographic Region/Country - US,
Europe and Rest of World Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) II-119

Table 9: World Historic Review for Angiogenesis Inhibitors by
Geographic Region / Country - US, Europe and Rest of World
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) II-120

Table 10: World 15-Year Perspective for Angiogenesis
Inhibitors by Geographic Region/Country - Percentage Breakdown
of Dollar Sales for US, Europe and Rest of World Markets for
Years 2003, 2011 and 2017 (includes corresponding Graph/Chart) II-121

Table 11: World Recent Past, Current & Future Analysis for
Angiogenesis Stimulators by Geographic Region/Country - US,
Europe and Rest of World Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) II-122

Table 12: World Historic Review for Angiogenesis Stimulators
by Geographic Region / Country - US, Europe and Rest of World
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) II-123

Table 13: World 15-Year Perspective for Angiogenesis
Stimulators by Geographic Region/Country - Percentage
Breakdown of Dollar Sales for US, Europe and Rest of World
Markets for Years 2003, 2011 and 2017 (includes corresponding
Graph/Chart) II-124

III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Angiogenic Inhibitors III-1
List of FDA Approved Anti-Angiogenic Drugs III-1
Pipeline Status By Disease III-2
Anti-Angiogenesis Therapeutics In Phase III Development
for Renal Cell Carcinoma: As of 2010 III-2
Anti-Angiogenesis Therapeutics In Phase III Development
for Breast Cancer Treatment: As of 2010 III-3
Angiogenesis Stimulators III-4
Historical Market Snapshots III-4
Market Influencers III-5
Types of Drug Approvals III-5
New Drug Approval (NDA) III-5
Orphan Drug Act III-5
Benefits Derived on Successful Grant of Orphan Drug Status III-5
Angiogenesis Foundation III-5
Key Role of the Foundation in Angiogenesis III-5
The Rising Concern III-6
Cancer III-6
Cancer Statistics in US III-6
A Picture of Colon Cancer in the US III-6
Pancreatic Cancer III-6
Vital Statistics III-7
Table 14: New Cancer Cases in the US By Affected Site:
2009 III-7

Table 15: New Cancer Cases in Males in US by Leading Site:
2009 (includes corresponding Graph/Chart) III-9

Table 16: New Cancer Cases in Females in US by Leading
Site:2009 (includes corresponding Graph/Chart) III-10

Table 17: Cancer Related Deaths in the US By Affected
Site:2009 III-11

Table 18: Cancer Related Deaths in Males in US by Leading
Site: 2009 (includes corresponding Graph/Chart) III-13

Table 19: Cancer Related Deaths in Females in US by
Leading Site: 2009 (includes corresponding Graph/Chart) III-14
AMD and DME Incidence in the US III-14
Rheumatoid Arthritis: Another Emerging Threat III-15
Diabetic Retinopathy III-15
Coronary Artery Disease (CAD) III-15
Myocardial Infarction Statistics in the US III-15
Peripheral Arterial Disease III-15
B.Market Analytics III-16
Table 20: The US Recent Past, Current & Future Analysis for
Angiogenesis Inhibitors & Stimulators by Product
Segments-Angiogenesis Inhibitors and Angiogenesis
Stimulators Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2009 through 2015 (includes
corresponding Graph/Chart) III-16

Table 21: The US Historic Review for Angiogenesis Inhibitors &
Stimulators by Product Segments- Angiogenesis Inhibitors
and Angiogenesis Stimulators Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2003 through 2008
(includes corresponding Graph/Chart) III-17

Table 22: The US 15-Year Perspective for Angiogenesis
Inhibitors & Stimulators by Product Segments - Percentage
Breakdown of Dollar Sales for Angiogenesis Inhibitors &
Stimulators for Years 2003, 2011 and 2017 (includes
corresponding Graph/Chart) III-18

2. EUROPE III-19
A.Market Analysis III-19
Angiogenesis Market - A Historic Perspective III-19
Cancer Trends III-19
Table 23: Cancer Incidence in Europe by Site (2009)
(includes corresponding Graph/Chart) III-20
B.Market Analytics III-21
Table 24: European Recent Past, Current & Future Analysis
for Angiogenesis Inhibitors & Stimulators by Product
Segments-Angiogenesis Inhibitors and Angiogenesis
Stimulators Markets Independently Analyzed with Annual
Sales in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-21

Table 25: European Historic Review for Angiogenesis
Inhibitors & Stimulators by Product Segments- Angiogenesis
Inhibitors and Angiogenesis Stimulators Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2003 through 2008 (includes corresponding
Graph/Chart) III-22

Table 26: European 15-Year Perspective for Angiogenesis
Inhibitors & Stimulators by Product Segments - Percentage
Breakdown of Dollar Sales for Angiogenesis Inhibitors &
Stimulators for Years 2003, 2011 and 2017 (includes
corresponding Graph/Chart) III-23

3. REST OF WORLD III-24
A.Market Analysis III-24
Japanese Market III-24
Quest for New Opportunities III-24
B.Market Analytics III-25
Table 27: Rest of World Recent Past, Current & Future
Analysis for Angiogenesis Inhibitors & Stimulators by
Product Segments-Angiogenesis Inhibitors and Angiogenesis
Stimulators Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-25

Table 28: Rest of World Historic Review for Angiogenesis
Inhibitors & Stimulators by Product Segments- Angiogenesis
Inhibitors and Angiogenesis Stimulators Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2003 through 2008 (includes corresponding Graph/Chart) III-26

Table 29: Rest of World 15-Year Perspective for Angiogenesis
Inhibitors & Stimulators by Product Segments - Percentage
Breakdown of Dollar Sales for Angiogenesis Inhibitors &
Stimulators for Years 2003, 2011 and 2017 (includes
corresponding Graph/Chart) III-27

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 69 (including Divisions/Subsidiaries - 85)

------------------------------------------
Region/Country Players
------------------------------------------
The United States 50
Canada 2
Japan 3
Europe 22
France 2
Germany 5
The United Kingdom 6
Italy 3
Rest of Europe 6
Asia-Pacific (Excluding Japan) 8
------------------------------------------

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos